Compare ODC & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ODC | DNA |
|---|---|---|
| Founded | 1941 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 706.2M | 607.1M |
| IPO Year | N/A | N/A |
| Metric | ODC | DNA |
|---|---|---|
| Price | $62.49 | $9.00 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.50 |
| AVG Volume (30 Days) | 75.6K | ★ 1.1M |
| Earning Date | 03-10-2026 | 02-25-2026 |
| Dividend Yield | ★ 1.27% | N/A |
| EPS Growth | ★ 17.33 | N/A |
| EPS | ★ 3.63 | N/A |
| Revenue | ★ $478,113,000.00 | $180,606,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.07 |
| P/E Ratio | $17.73 | ★ N/A |
| Revenue Growth | ★ 5.29 | N/A |
| 52 Week Low | $41.37 | $5.00 |
| 52 Week High | $69.76 | $17.58 |
| Indicator | ODC | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 61.23 | 47.42 |
| Support Level | $57.35 | $8.65 |
| Resistance Level | $67.25 | $9.61 |
| Average True Range (ATR) | 1.64 | 0.79 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 52.12 | 47.17 |
Oil-Dri Corp of America develops, manufactures, and markets sorbent products made predominantly from clay. Its absorbent offerings, which draw liquid up, include cat litter, floor products, toxin control substances for livestock, and agricultural chemical carriers. The company has two segments based on the different characteristics of two primary customer groups, namely the Retail and Wholesale Products Group, which derives maximum revenue, and the Business-to-Business Products Group. The company's products are sold under various brands such as Cat's Pride, Jonny Cat, Amlan, Agsorb, Verge, Pure-Flo, and Ultra-Clear.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.